Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GlaxoSmithKline launches hunt for new chief executive

Drug group is said to have kicked off succession planning, but it is in no rush to replace Witty
GlaxoSmithKline launches hunt for new chief executive
Chief executive Andrew Witty is not expected to leave until next year at the earliest

British drug giant GlaxoSmithKline (LON:GSK) is launching a hunt for a new chief executive to succeed Andrew Witty, it emerged on Monday.

Chairman Philip Hampton is said to have told shareholders that the company's board will prioritise succession planning in the next couple of years, although Witty is not expected to go until next year at the earliest.

Hampton is in no rush and is keen to ensure a considered and orderly transition, Reuters cited unidentified sources as saying. Witty himself is said to be set to play a role in finding his successor.

There has been speculation about takeover interest in Glaxo and some shareholders have called on the company to consider breaking itself up.

Witty, who has faced criticism from some about Glaxo's relatively lacklustre share price, has insisted Glaxo is better off intact than splitting itself into its constituent parts, such as pharmaceuticals and consumer health.

He told a news conference earlier this month: “When you look at the uncertainty of the general global environment, I actually think having a more balanced set of businesses is exactly the right course for us.”

Shares in Glaxo rose 3p to 1413.5p in early London trading.

 

Phil-Waller.jpg


Register here to be notified of future GSK Company articles
View full GSK profile

GlaxoSmithKline plc Timeline

Video
February 22 2017
Article
February 08 2017

Related Articles

Blood test
September 27 2016
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth
Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln
eye-766166_1280_583251a48f148.jpg
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use